Clinical Trial: Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Previously Treated With Imatinib

Brief Summary: This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg. [ Time Frame: every 8 weeks ]

Original Primary Outcome: To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.

Current Secondary Outcome: To determine progression-free survival and the response rate of nilotinib in patients with advanced GIST previously treated with imatinib ≥600 mg. [ Time Frame: 6 months ]

Original Secondary Outcome: Same as current

Information By: Novartis

Dates:
Date Received: April 22, 2010
Date Started: September 2008
Date Completion:
Last Updated: February 24, 2017
Last Verified: February 2017